Coverage
Filings
| Filing | Date |
|---|---|
| China Breakthrough Therapy Designation for Blenrep | 13 Sept 2024 |
| Positive mRNA flu vaccine Phase II headline data | 12 Sept 2024 |
| Director/PDMR Shareholding | 12 Sept 2024 |
| Update on phase I/II therapeutic HSV vaccine trial | 11 Sept 2024 |
| Change of Registered Office | 11 Sept 2024 |
| Statement: Zantac (ranitidine) litigation | 11 Sept 2024 |
| Depemokimab late-breaking data presented at ERS | 9 Sept 2024 |
| Positive Phase III results for Nucala in COPD |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 6 Sept 2024 |
| Director/PDMR Shareholding | 6 Sept 2024 |
| Total Voting Rights | 2 Sept 2024 |
| EMA approval on Arexvy for 50-59 at risk | 29 Aug 2024 |
| Statement: Zantac (ranitidine) litigation | 28 Aug 2024 |